Free Trial
LON:VENN

Venn Life Sciences (VENN) Share Price, News & Analysis

Venn Life Sciences logo

About Venn Life Sciences Stock (LON:VENN)

Key Stats

Today's Range
N/A
50-Day Range
6.85
6.85
52-Week Range
N/A
Volume
1.03 million shs
Average Volume
566,253 shs
Market Capitalization
£4.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Venn Life Sciences Holdings Plc, a clinical research organization, provides consulting and clinical trial services to pharmaceutical, biotechnology, and medical device companies in the United Kingdom, Ireland, France, the Netherlands, Germany, and Singapore. The company offers drug development planning and strategy services, including clinical feasibility assessment, project management, and in-licensing and technical due diligence; and early drug development services, such as drug candidate selection, CMC, non-clinical/pre-clinical development, clinical pharmacology, pharmacokinetics, and pharmacometrics and PK-PD modelling. It also provides clinical trial services comprising clinical feasibility assessment, project management, clinical and medical monitoring, biometrics, biostatistics, data management and databases integration, ISC/IDMC, RTSM, investigator initiated studies, and resourcing and recruitment. In addition, the company offers regulatory affairs and consulting, quality assurance, and legal services, as well as drug development training and courses. The company has a strategic collaboration with Open Orphan DAC for the clinical research and regulatory consulting for companies developing products under the auspices of the various Orphan Drug frameworks. The company was founded in 2012 and is headquartered in Dublin, Ireland.

Receive VENN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Venn Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

VENN Stock News Headlines

The Group Chat That Secretly Runs Congress
Media Is Mocking Elon, But Wait Until They See This Demo
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
See More Headlines

VENN Stock Analysis - Frequently Asked Questions

Shares of VENN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Venn Life Sciences investors own include Nielsen (NLSN), Bank of Hawaii (BOH), BJ's Wholesale Club (BJ), Biogen (BIIB), Bank of America (BAC), Arrow Electronics (ARW) and Art's-Way Manufacturing (ARTW).

Industry, Sector and Symbol

Sector
N/A
Industry
Medical Care
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
157
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
GBX 15.60 per share

Miscellaneous

Free Float
N/A
Market Cap
£4.89 million
Optionable
Not Optionable
Beta
N/A
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (LON:VENN) was last updated on 12/7/2024 by MarketBeat.com Staff
From Our Partners